Anavex Life Sciences Corp. (LON:0HFR)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 600.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.16M |
| Shares Out | n/a |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | 5.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,383 |
| Average Volume | 5,051 |
| Open | 9.68 |
| Previous Close | 9.67 |
| Day's Range | 9.32 - 9.74 |
| 52-Week Range | 4.95 - 14.45 |
| Beta | 0.80 |
| RSI | 35.53 |
| Earnings Date | Aug 12, 2025 |
About Anavex Life Sciences
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept stud... [Read more]
News
Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows
Anavex Life Sciences Corp. (NASDAQ: AVXL) reported a peer-reviewed publication in the journal Neuroscience Letters on Wednesday. The study shows that a pre-treatment with blarcamesine prevented Amylo...
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease
Pre-Treatment with blarcamesine entirely prevented Abeta-induced cognitive decline Confirmed significant biomarker-response in hippocampus NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Anavex Life Scien...
Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call Transcript
Anavex Life Sciences GAAP EPS of -$0.16 misses by $0.02
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ: SFD) is expected to report quarterly earnings at $0.55 per share on revenue of $3.62 billion. • Venture Global (NYSE: VG) is estimated...
What to Expect from Anavex Life Sciences's Earnings
Anavex Life Sciences (NASDAQ: AVXL) will release its quarterly earnings report on Tuesday, 2025-08-12. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Anavex Life...
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
Webcast and Conference Call To be Held Tuesday, August 12, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, August 12, 2025, 8:30 am ET
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved' by early-start
Anavex Life Sciences files $300M common stock offering
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the Firm
PHILADELPHIA, June 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Anavex Life Sciences Corp. (NASD...
Does Anavex's Alzheimer's Drug Actually Confer Benefit?
Anavex Life Sciences' OLE study demonstrates that its Alzheimer's drug works for years beyond the clinical study. The OLE expands efficacy to include patients' behavioral abilities. The Anavex drug ma...
The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)
Blarcamesine shows limited effectiveness against mild Alzheimer's disease, but not against moderate Alzheimer's. However, it does appear effective when started early. These result could lead to Europ...
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and...
Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript
Anavex Life Sciences GAAP EPS of -$0.13 beats by $0.02
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time
Earnings Scheduled For May 13, 2025
Companies Reporting Before The Bell • Endeavour Silver (NYSE: EXK) is estimated to report quarterly earnings at $0.03 per share on revenue of $60.52 million. • Intl Game Tech (NYSE: IGT) is expected...
An Overview of Anavex Life Sciences's Earnings
Anavex Life Sciences (NASDAQ: AVXL) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Anavex Life...
Anavex Life Sciences Q2 2025 Earnings Preview
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants Both Part A (16 participants) and Part B (55 participants) of the placebo-controlled Phase 2 study fully enrol...
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatme...